Ondine Biomedical (LON:OBI) Stock Price Down 2.4% – Should You Sell?

Ondine Biomedical Inc. (LON:OBI) shares fell 2.4% during mid-day trading on Wednesday . The stock traded as low as C$10.00 and last traded at C$10.00. 6,261 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 313,582 shares. The stock had previously closed at C$10.25.

Ondine Biomedical Price Performance

The company has a current ratio of 1.36, a quick ratio of 8.26 and a debt-to-equity ratio of 25.95. The stock has a market cap of C$71.90 million, a PE ratio of -3.01 and a beta of 0.10. The business has a 50-day moving average price of C$11.30 and a 200 day moving average price of C$8.94.

Insider Buying and Selling at Ondine Biomedical

In other Ondine Biomedical news, insider Carolyn Cross bought 200,775 shares of the stock in a transaction on Thursday, January 30th. The shares were acquired at an average price of C$12.00 per share, with a total value of C$2,409,300.00. Insiders own 36.69% of the company’s stock.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.